Abstract
In 2020, many patients were infected with the coronavirus disease 2019 (COVID-19) worldwide. The identification of coronavirus in saliva have suggested the oral cavity as a potential reservoir for COVID-19 transmission, particularly in dental clinics. Chairside oral rinses have been widely used as a standard measure before routine dental treatment for many years. Recently, the use of chairside oral rinse has been recalled as a pre-procedural infection control measure by several health authorities, especially during the COVID-19 pandemic. Although there is still no clinical evidence, oral rinses containing active oxygen agents (e.g. BlueM formula) have been recommended to reduce the viral load in aerosols and drops during oral procedures. This paper aimed to provide an overview of the current guidelines and recommendations on the use of active oxygen oral rinse as chairside treatment against the COVID-19 pandemic in dentistry.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal Of Community Medicine And Public Health
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
